Introduction
============

Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) constitute the most common primary liver malignancies[@B1]. CHC is a rare type of primary liver cancer that shares the histopathologic characteristics of both cholangiocarcinoma (CC) and HCC[@B2]. According to the latest WHO classification of the digestive system, CHC is divided into two histological types: a classical type and subtypes with stem cell features[@B3].

The imaging characteristics of HCC and ICC have been widely investigated by contrast-enhanced MRI or CT. CHC may share typical features with HCC and ICC, such as arterial enhancement and portal washout, whereas the remaining tumor regions may show a delayed enhancement and biliary ductal dilation\[2, 4\]. Taken together, the preoperative diagnosis of CHC remains a challenge. Some clinicians suggest that the discordance between imaging features and the elevation of tumor marker levels could indicate CHC\[2, 4, 5\].

Due to the low prevalence of CHC, the clinical characteristics of this disease are poorly understood. Some studies indicated that CHC may show clinical characteristics resembling HCC, but the OS was more similar to that of ICC\[6\]. Surgical resection remains the treatment of choice for CHC patients and yields better survival benefits than other treatment options\[1, 6, 7\].

In retrospective studies, the propensity score analysis has been widely used to reveal the true treatment effect by balancing the confounders between younger patients and elderly patients^\[8-10\]^. Several studies have demonstrated by PSM analysis that HCC and ICC have comparable long-term OS and DFS in younger and elder ^\[11-15\]^. However, to date, no study has evaluated the effect of age after hepatectomy in CHC patients. In the present study, the prognostic factors that influence OS and DFS was analyzed. Thereby, PSM analysis was adopted to remove bias caused by these factors in order to reveal the true effect of age.

Patients and Methods
====================

Study Population and Data Collection
------------------------------------

Between March 1993 and December 2014, 269 patients diagnosed with pathologically confirmed CHC were recruited at the Department of Liver Surgery, Zhongshan Hospital. Surgical techniques for liver resection were described elsewhere\[16\], and the pathology of CHC was diagnosed according to World Health Organization criteria\[3\]. Preoperative imaging examinations including chest X-ray, abdominal ultrasonography, contrast-enhanced computer tomography (CT) or magnetic resonance imaging (MRI), were performed routinely. Serum biochemical and prothrombin time data and the presence of ascites were used to assess liver function. Patients with Child A cirrhosis, and early Child B cirrhosis were considered for resection: the former were offered resections up to 50%, while the latter were offered up to 25%\[17\]. Eight patients were excluded for other therapeutic modalities, 11 patients were excluded due to missing data, 25 patients were excluded for preoperative therapy, four patients were excluded due to recurrence within one month after surgery, and eight patients dropped out of the study. Overall, 213 patients were included in the study. The patients were categorized into two groups, the "younger" group (age \<60, n=161) and the "elderly" group (age ≥60, n=52). The study was approved by the Institutional Review Board of the Zhongshan Hospital and complied with the standards of the Declaration of Helsinki and current ethical guidelines.

Follow up
---------

Patients were followed up every 3 months until death or dropping out of the follow-up program. Abdominal ultrasound, liver function tests, serum alpha-fetoprotein (AFP) levels, carcinoembryonic antigen (CEA) levels and carbohydrate antigen 19-9 (CA19-9) levels were analyzed every 3 months, and abdominal magnetic resonance imaging (MRI) was performed every 6 months. The end-point of the study was overall survival (OS), which was defined as the interval between the date of surgery and the date of the patient\'s death or final follow-up.

The diagnosis of recurrence was based on MRI imaging findings, increased serum AFP and CA19-9 levels. Extrahepatic recurrence was also examined by chest CT and bone scintigram. Based on the recurrence pattern and the liver function reserve, the patients were managed with different therapeutic modalities, including radiofrequency ablation (RFA), repeated resection for resectable recurrence, TACE, percutaneous ethanol injection (PEI), and chemotherapy for patients with extrahepatic metastatic disease.

Statistical Analysis
--------------------

Demographic, clinical and tumor characteristics are described as summary statistics, which were obtained using established methods. In both younger and elderly cohorts, continuous data were presented as the mean and the 25th-75th percentile range and analyzed using the Mann-Whitney U test. The categorical variables were described as absolute and relative frequencies and compared using Pearson χ^2^ analysis or the Fisher exact test. OS and DFS were compared using the Kaplan-Meier method, and the survival differences between the two groups were compared using the log-rank test.

Logistic regression was used for the propensity score matching analysis to estimate the propensity score (from 0 to 1), which contains information on the variates selected. To create a reliable propensity score model, the variables chosen for matching should include all the potential confounders. ^\[8-10\]^ Instead, the variables should contain all the independent prognostic factors of CHC. The Cox proportional hazards model was used to identify the independent prognostic factors. Then, the statistically significant variables (P\<0.1) obtained from the univariate analysis were used in the multivariate analysis. The variables entered in the final propensity model were gender, the serum level of carcinoembryonic antigen, ɣ-glutamyl transpeptidase (GGT), macroscopic vascular invasion (MVI), portal lymph node invasion and extrahepatic metastases. The model used the one-to-one match without replacement between younger and elderly patients using the nearest-neighbor matching algorithm. The caliper value was set to 0.01, and the balance between the two groups after matching was evaluated by the standardized mean difference (\<0.1).

All tests using a two-tailed*P*-value \<0.05 were considered to be statistically significant. All statistical analyses were performed using the SPSS 22.0 statistical package (SPSS Incorporated, Chicago, Illinois, USA) and the design and survival packages. This project was approved by our institutional review board.

Results
=======

Demographic and Clinicopathological Characteristics
---------------------------------------------------

The demographic and clinicopathological characteristics are shown in **Table [1](#T1){ref-type="table"}.** The mean age of the entire cohort was 52.4 years. One quarter of the patients were ≥60 years old (n=52, 24.3%), whereas the remaining patients were \<60 years old (n=161, 75.7%). A higher proportion of the younger patients had HBV infection (P\<0.001). In contrast, the elderly patients had a poor liver function (P=0.027), a high occurrence of abnormal serum albumin (P\<0.001) and the presence of ascites (P=0.011). For the tumor characteristics, the elderly patients showed a high occurrence of portal lymph node invasion (P=0.024).

The prognostic factors of combined hepatocellular carcinoma-cholangiocarcinoma
------------------------------------------------------------------------------

To identify the potential confounders, the Cox proportional hazards model was used to analyze the risk factors of CHC (**Table [2](#T2){ref-type="table"}**). With regard to OS, the following 12 variates determined by the univariate analysis were included in the multivariate analysis: gender (male), the Child-Pugh grade, CEA, CA19-9, albumin, GGT, tumor number, tumor size, MVI, portal lymph node invasion, and extrahepatic metastases. The multivariate analysis revealed that CEA, GGT, MVI, lymphoid metastases, and extrahepatic metastases were independent prognostic factors of OS. For DFS, the following 4 variates determined by univariate analysis were included in the multivariate analysis: gender, GGT, MVI and portal lymph node invasion. The multivariate analysis indicated that gender, MVI, and portal lymph node invasion were independent risk factors for predicting a poor DFS. Age was not an independent factor for OS (P=0.190) or DFS (P=0.292) in either the univariate or multivariate analyses.

Propensity score matching for younger and elderly patients
----------------------------------------------------------

The distributions of the risk factors and demographic characteristics differ between the younger and elderly groups. To reduce confounding and to reflect the true effect of age, a propensity score matching model was built based on the analysis of the risk factors above. Considering OS and DFS, seven variates contributed to the model: gender, CEA, and ɣ-GT, MVI, lymphoid metastases and extrahepatic metastases. Therefore, 46 pairs of elderly patients and younger patients were finally matched. The comparisons between the two groups are shown in **Table [3](#T3){ref-type="table"}**.

OS and DFS
----------

The median survival of the entire cohort was 25 months, and the overall cumulative survival rates at 1, 3 and 5 years were 73.2%, 39.0%, and 28.3%, respectively. Stratified by age, the median overall survival of the elderly patients was lower than that of the younger patients (18.0 months vs 27.16 months). The cumulative survival rates of the elderly patients at 1, 3 and 5 were 70.3%, 40.0% and 22.2%, whereas in younger patients, they were 75.2%, 42.5% and 30.3%, respectively. The OS rates were comparable between the younger and elderly patients (**Figure [1](#F1){ref-type="fig"}A**). After propensity score matching, the median OS was higher in the younger patients than in the elderly patients (24 months vs 18 months). The survival rates of 1, 3 and 5 years in younger patients were 78.7%, 32.5% and 20.3%, whereas in elderly patients they were 74.0%, 31.7% and 23.8%, respectively. However, the OS between the younger and elderly patients remains comparable (**Figure [1](#F1){ref-type="fig"}B**). Regarding the DFS, the median disease-free survival of the entire cohort was 32 months. The DFS was comparable between the younger and elderly patients before and after propensity score matching (**Figure [1](#F1){ref-type="fig"} C & D**).

Discussion
==========

CHC is a rare primary liver tumor that constitutes only 2.4% to 14.2% of all primary hepatic malignancies^\[1,\ 2,\ 18-20\]^. The CHC had a dual differentiation of both bile duct epithelia and hepatocytes within the same tumor^\[1,\ 2\]^. The biological and pathological behaviors of these tumors are complex, and aggressive liver resection may provide a better prognosis[@B1]. The effect of age on the long-term prognosis of hepatic resection with in patients diagnosed with HCC or ICC has been extensively studied, but the results are conflicting. Propensity score matching, a new statistical method, revealed that long-term OS and DFS in elderly and younger patients with either HCC or ICC are comparable ^\[11-15\]^. Although previous studies noted that CHC was more common in male patients older than 65 years[@B21], the effect of age on the long-term prognosis of patients with CHC who underwent curative surgery had not been studied. Thus, a total of 269 patients who underwent hepatic resection for CHC at a single center was examined and analyzed OS and DFS by propensity score analysis and multivariate analysis. Due to a lack of typical imaging characteristics, preoperative diagnosis of CHC remains difficult. Thus, most patients with CHC were misdiagnosed either as having HCC or CC before the surgery^\[4,\ 22\]^. Surgical resection remains the main treatment for primary liver tumors; however, whether elderly patients may benefit from aggressive surgical treatment has not been agreed upon. Previous studies have noted that, compared to younger patients, elderly patients with HCC or ICC have a comparable OS and DFS after hepatectomy as revealed by propensity score matching ^\[11-15\]^. Consistent with these studies, the OS and DFS were not significantly different between younger and elderly patients. Although elderly patients are more likely to have a worse liver function reserve and lymphoid metastases, the effect of age on the long-term prognosis was not obvious after adjusting the main confounding factors using propensity score matching or multivariate analysis. To date, the present study represents the first study to assess the effect of age on the long-term prognosis of patients who underwent resection for CHC.

To further reveal the true effect of age on the long-term prognosis of surgical patients with CHC, the confounding factors must be balanced between the younger and elderly patients. In the propensity score matching analysis, regardless of whether the included variates differed between the two groups before matching, the distributions of the selected variates were comparable between the matched pairs selected by the model. Thus, a multivariate analysis of the prognosis was performed in the entire cohort to identify the independent risk factors of CHC. Consistent with previous studies^\[6,\ 21,\ 23-26\]^, age was not identified as an independent factor in the multivariate analysis. Moreover, consistent with the multivariate analysis OS and DFS did not differ significantly between the younger and elderly patients after propensity score matching, suggesting that the younger and elderly patients with CHC and similar demographic characteristics and clinicopathological features had comparable long-term prognoses. Taken together, these findings suggest that hepatic resection surgery should be considered as a potential treatment in elderly patients, as elderly patients can achieve long-term survivals that are comparable to those of younger patients.

There is a clear consensus that a high prevalence of chronic HBV infection is the most common etiological factor of HCC[@B27], and HBV infection has been related to an increased risk of CC[@B28] .HBV can integrate into the host genome, disrupt the expression of host genes and cause hepatocarcinogenesis even without hepatic fibrosis of cirrhosis[@B29].Recently, it has been shown that HBV infection and heavy alcohol consumption may contribute to the development of CHC[@B30]. Consistent with the previous studies, the percentage of HBV-positive patients with CHC (74.6%, 159/213) is much higher than normal population in our study[@B31]. The younger patients have a higher rate of HBV infection when compared to elderly patients (83.9% vs 46.2%, P\<0.001), suggesting that CHC may partially share a similar mechanism with HCC------HBV infection often occurs in early childhood, and the hepatocarcinogenesis can often be observed under the influence of decades of HBV infection. However, in the subsequent study, multivariate analysis indicated that HBV infection was not an independent risk factor associated with OS or DFS. It suggesting that HBV infection was not a solid contributor to CHC prognosis, as CHC also shares the histopathologic characteristics of cholangiocarcinoma^\[23,\ 30\]^.

Several limitations of the current study may have influenced the results. Given the nature of the retrospective study, there could be potential unmeasurable confounders between the two groups. Additionally, due to the low prevalence of this tumor, even though the research population is largest so far, the sample size is still relatively small and may affect the statistical power. In recent years, given the technical advancement of hepatectomy, the selection criteria have broadened, especially for elderly patients, which resulted in shorter follow-up times in the elderly group.

In conclusion, the long-term OS and DFS in younger and elderly patients who underwent liver resection for CHC are comparable. Moreover, tumor characteristics, such as MVI and extrahepatic metastases, are more powerful predictors of an unfavorable prognosis. In summary, an aggressive resection strategy could be recommended for elderly patients who have tumor characteristics that are like younger patients.
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###### 

Comparison of Demographic Data and Outcomes Between Younger (≤60 Years of Age) and Elderly (\>60 Years of Age) Patients With CHC

  -----------------------------------------------------------------------------------------------
                                Total\          Younger patients\   Elderly patients\   P value
                                (n=213)         (n=161)             (n=52)              
  ----------------------------- --------------- ------------------- ------------------- ---------
  Age (yrs.)                    52.4±8.7        47.4±8.7            67.7±4.9            \<0.001

  Gender: Male                  161 (75.6%)     123 (76.4%)         38 (73.1%)          0.682

  HBV: Positive                 159 (74.6%)     135 (83.9%)         24 (46.2%)          \<0.001

  HCV: Positive                 5 (2.3%)        3 (1.9%)            2 (3.8%)            0.597

  **Child-Pugh Class**                                                                  

  A                             202 (94.8%)     156 (96.9%)         46 (88.5%)          0.027

  B                             11 (5.2%)       5 (3.1%)            6 (11.5%)           

  **AFP (ng/ml)**                                                                       

  ≤20                           99 (46.5%)      76 (47.2%)          23 (44.2%)          0.622

  \>20                          114 (53.5%)     85 (52.8%)          29 (55.8%)          

  **CEA (ng/ml)**                                                                       

  ≤5                            174 (81.7%)     132 (82%)           42 (80.8%)          0.911

  \>5                           39 (18.3%)      29 (18%)            10 (19.2%)          

  **CA199 (U/ml)**                                                                      

  ≤37                           140 (65.7%)     106 (65.8%)         34 (65.4%)          0.862

  \>37                          73 (34.3%)      55 (34.2%)          18 (34.6%)          

  TB (μmol/L): \>17             41 (18.8%)      29 (17.6%)          12 (22.6%)          0.674

  ALB (g/L): \<40               73 (33.5%)      45 (27.3%)          28 (52.8%)          0.001

  ALT (U/L): \>35               90 (41.3%)      72 (43.6%)          18 (34%)            0.213

  GGT (U/L): \>40               155 (71.1%)     114 (69.1%)         41 (77.4%)          0.248

  Ascites (ml)                                                                          

  No                            193 (90.6%)     151 (93.8%)         42 (80.8%)          0.011

  Yes                           20 (9.4%)       10 (6.2%)           10 (19.2%)          

  **Tumor nodularity**                                                                  

  Single                        159 (74.6%)     118 (73.3%)         41 (78.8%)          0.423

  Multiple                      54 (25.4%)      43 (26.7%)          11 (21.2%)          

  Tumor Diameter (cm)           6.4 (3.5-8.0)   6.4 (3.5-8.0)       6.4 (3.3-7.7)       0.852

  **Macroscopic VI**                                                                    

  No                            200 (93.9%)     151 (93.8%)         49 (94.2%)          1.000

  Yes                           13 (6.1%)       10 (6.2%)           3 (5.8%)            

  **Microscopic VI**                                                                    

  No                            167 (78.4%)     124 (77%)           43 (82.7%)          0.309

  Yes                           46 (21.6%)      37 (23%)            9 (17.3%)           

  **Lymphoid Metastases**                                                               

  No                            188 (88.3%)     147 (91.3%)         41 (78.8%)          0.024

  Yes                           25 (11.7%)      14 (8.7%)           11 (21.2%)          

  **Extrahepatic Metastases**                                                           

  No                            206 (96.7%)     156 (96.9%)         50 (96.2%)          0.678

  Yes                           7 (3.3%)        5 (3.1%)            2 (3.8%)            
  -----------------------------------------------------------------------------------------------

###### 

Prognostic Analysis of Overall Survival and Disease-free Survival Before Propensity Score Matching

                                         Overall survival                  Disease-free survival                                                                                                 
  -------------------------------------- ----------------------- --------- ----------------------- ---------------------- --------- -- ---------------------- --------- -- --------------------- ---------
  Age (yrs.): \>60 vs ≤60                1.326 (0.869-2.023)     0.190                                                                 1.306 (0.795-2.145)    0.292                              
  Gender: Male vs Female                 1.507 (0.955-2.378)     0.078                             1.501 (0.917-2.456)    0.106        1.928 (1.101-3.375)    0.022        2.453 (1.339-4.495)   0.004
  Child-Pugh Class: B vs A               1.942 (0.940-4.015)     0.073                             1.523 (0.691-3.357)    0.296        0.846 (0.267-2.688)    0.777                              
  Comorbid illness: Yes vs No            1.336 (0.921-1.937)     0.127                                                                 1.083 (0.706-1.661)    0.715                              
  HBV: Positive vs Negative              0.962 (0.644-1.437)     0.849                                                                 1.477 (0.868-2.512)    0.150                              
  HCV: Positive vs Negative              2.502 (0.784-7.983)     0.121                                                                 0.818 (0.113-5.907)    0.842                              
  AFP (ng/ml): \>20 vs ≤20               0.879 (0.614-1.259)     0.482                                                                 0.832 (0.544-1.272)    0.396                              
  CEA (ng/ml): \>5 vs ≤5                 1.597 (1.050-2.428)     0.029                             1.628 (1.045-2.538)    0.031        0.825 (0.465-1.464)    0.512                              
  CA199 (U/ml): \>37 vs ≤37              1.514 (1.053-2.176)     0.025                             1.117 (0.763-1.635)    0.571        1.004 (0.639-1.578)    0.985                              
  TB (μmol/L): \>17 vs ≤17               0.938 (0.599-1.471)     0.781                                                                 1.000 (0.593-1.685)    1.000                              
  ALB (g/L): \<40 vs ≥40                 1.318 (0.909-1.911)     0.145                                                                 1.213 (0.771-1.909)    0.405                              
  ALT (U/L): \>35 vs ≤35                 1.285 (0.900-1.834)     0.168                                                                 1.644 (1.074-2.516)    0.022        1.394 (0.896-2.169)   0.141
  GGT (U/L): \>40 vs ≤40                 2.711 (1.700-4.323)     \<0.001                           2.069 (1.228-3.485)    0.006        1.866 (1.125-3.095)    0.016        1.367 (0.801-2.332)   0.251
  Ascites: Yes vs No                     1.410 (0.809-2.458)     0.226                             1.799 (0.971-3.333)    0.062        0.501 (0.187-1.342)    0.169                              
  Tumor Nodularity: Multiple vs Single   1.557 (1.055-2.298)     0.026                             1.484 (0.986-2.233)    0.059        1.224 (0.758-1.976)    0.408                              
  Tumor Diameter (cm): \>5 vs ≤5         2.424 (1.665-3.530)     \<0.001                           1.320 (0.870-2.002)    0.192        1.429 (0.929-2.196)    0.104                              
  Macroscopic VI: Yes vs No              3.805 (2.070-6.993)     \<0.001                           3.211 (1.765-5.841)    \<0.001      5.089 (2.371-10.922)   \<0.001      3.602 (1.647-7.879)   0.001
  Microscopic VI: Yes vs No              1.437 (0.944-2.188)     0.090                             1.542 (0.994-2.394)    0.053        1.192 (0.708-2.007)    0.508                              
  Lymphoid Metastases: Yes vs No         2.822 (1.699-4.686)     \<0.001                           2.481 (1.358-4.530)    0.003        2.454 (1.342-4.486)    0.004        3.297 (1.710-6.357)   \<0.001
  Extrahepatic Metastases: Yes vs No     11.186 (4.900-25.536)   \<0.001                           5.060 (2.026-12.639)   0.001        2.987 (0.710-12.566)   0.135                              

###### 

Characteristics of Patients before and after Propensity Score Matching

                            Before Matching                After Matching                                
  ------------------------- ----------------- ------------ ---------------- -- ------------ ------------ -------
  Age (yrs.)                47.6±8.6          67.7±5.0     2.872               47.0±8.2     67.5±5.1     3.015
  Gender                                                                                                 
  Female                    38 (23.6%)        14 (26.9%)   0.076               8 (17.4%)    8 (17.4%)    0.000
  Male                      123 (76.4%)       38 (73.1%)   0.076               38 (82.6%)   38 (82.6%)   0.000
  CEA (ng/ml):                                                                                           
  \>5                       132 (82%)         42 (80.8%)   0.031               39 (84.8%)   39 (84.8%)   0.000
  ≤5                        29 (18%)          10 (19.2%)   0.031               7 (15.2%)    7 (15.2%)    0.000
  GGT (U/L)                                                                                              
  \>40                      50 (31.1%)        12 (23.1%)   0.180               11 (23.9%)   11 (23.9%)   0.000
  ≤40                       111 (68.9%)       40 (76.9%)   0.180               35 (76.1%)   35 (76.1%)   0.000
  Macroscopic VI                                                                                         
  No                        151 (93.8%)       49 (94.2%)   0.019               44 (95.7%)   44 (95.7%)   0.000
  Yes                       10 (6.2%)         3 (5.8%)     0.019               2 (4.3%)     2 (4.3%)     0.000
  Lymphoid Metastases                                                                                    
  No                        147 (91.3%)       41 (78.8%)   0.355               39 (84.8%)   39 (84.8%)   0.000
  Yes                       14 (8.7%)         11 (21.2%)   0.355               7 (15.2%)    7 (15.2%)    0.000
  Extrahepatic Metastases                                                                                
  No                        156 (96.9%)       50 (96.2%)   0.040               45 (97.8%)   45 (97.8%)   0.000
  Yes                       5 (3.1%)          2 (3.8%)     0.040               1 (2.2%)     1 (2.2%)     0.000

Note: Values in *n* (%), mean ± standard deviation.Std. mean difference: standardized mean difference
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